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Abstract
Background: Varenicline and bupropion, efficacious smoking cessation medications, have had suboptimal impact
due to barriers at the patient, practitioner and system level. This study explored the feasibility of a web-assisted
tobacco intervention offering free prescription smoking cessation medication by mail if the smoker visited a
physician for authorization.
Methods: Adult Ontarians, smoking at least 10 cigarettes daily, intending to quit within 30 days, with no
contraindications to bupropion or varenicline were eligible. After an online assessment, eligible participants
received an electronic personalized printable prescription form for a 12-week course of varenicline or bupropion to
bring to a physician within 3 weeks for authorization, if appropriate. The physician’s office faxed prescriptions to an
online pharmacy that couriered medication to the patient following medication counselling by telephone. Weekly
motivational emails were sent during treatment. Participants were asked to complete follow-up questionnaires
online at 7, 11, 15 and 41 weeks after enrollment.
Results: In total, 1214 individuals submitted an online assessment from April to September 2010 and 73.6 %
(95 % confidence interval (CI) = 71.1–76.1 %; n = 893) were eligible. At least 65.8 % (95 % CI = 62.7–68.9 %; n = 588)
of eligible participants subsequently visited a physician and 58.7 % (95 % CI = 55.5–61.9 %; n = 524) received
medication (50.6 % varenicline [n = 265] and 49.4 % bupropion [n = 259]). Reasons for not filling a prescription were
failure to visit a physician (80.1 %; 95 % CI = 73.8–86.5 %; n = 121), physician not prescribing the medication
(15.9 %; 95 % CI = 10.1–21.7 %; n = 24) or other reasons (4.0 %; 95 % CI = 0.9–7.1 %; n = 6). Follow-up response rate
was 66.7 % (95 % CI = 63.7–69.8 %; n = 596). Minimal issues were encountered with printing the prescription or
medication delivery.
Conclusions: This study establishes the feasibility of using the Internet and free medication to enable smokers to
engage physicians to treat this addiction. Implementation of this intervention can be scaled up by leveraging
existing healthcare systems to treat smokers on a population level. Further evaluation in a randomized controlled
trial is necessary.
Trial registration: ClinicalTrials.gov Identifier NCT01023659
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Background
Each year, approximately six million people worldwide
die prematurely due to tobacco-related diseases [1]. For
each person who dies from a smoking-related disease,
approximately 30 more people have at least one serious
medical condition caused by smoking [2]. The majority
of smokers want to quit [3, 4] but find it difficult [5].
Each year, close to half of smokers in North America
make a quit attempt [4, 6], but without assistance only
3–5 % achieve long-term abstinence [7]. Several smoking
cessation medications have been shown to improve
long-term abstinence rates [8, 9], but despite their
proven efficacy, approximately two-thirds of smokers re-
port not having used medication in their most recent
quit attempt [10].
Barriers to the use of these medications exist at the pa-
tient, system and practitioner level. Patient-level barriers
include poor awareness, perceived lack of effectiveness,
low desirability including concern regarding adverse ef-
fects, and poor accessibility of treatment [11, 12]. Acces-
sibility issues include anticipated difficulties obtaining a
prescription from a physician and perceived high cost of
medication [11]. Full coverage of the cost of smoking
cessation medications has been proven to increase
utilization and improve quit rates [13, 14]. Advice by a
healthcare provider to quit smoking has also been asso-
ciated with increased use of smoking cessation treat-
ments [15]. Though evidence-based clinical practice
guidelines recommend that every smoker be advised to
quit and assisted if ready to make a quit attempt [16, 17],
a recent Canadian survey found that of the smokers who
visited a physician in the previous 12 months, only 56 %
received advice to quit and 34 % received information
about smoking cessation aids [4].
Passive dissemination of guideline recommendations is
generally ineffective in changing practitioner behaviour,
and more intensive (and costly) training is generally ne-
cessary to alter practice [18]. Strategies to promote im-
plementation of smoking cessation guidelines are most
often targeted to clinicians [19]. Healthcare professionals
who have received training for delivery of smoking
cessation interventions are more likely to perform
cessation-related tasks such as asking patients to set a
quit date, offer counselling and provide self-help mate-
rials [20]. However, a Cochrane review found no demon-
strated effect of training on provision of smoking
cessation medications [20]. Therefore, new methods are
required to enhance the prescribing of these evidence-
based medications, which almost double to triple the
odds of long-term cessation [8]. There is evidence that
interventions targeted to patients can also change clin-
ician practice and improve care [19, 21]. Patient-
mediated interventions are delivered to patients with the
aim of changing the attitudes, knowledge, skills and/or
behaviour of the healthcare provider via patient-provider
interaction [22]. Empowering patients to take an active
role in their treatment in this manner may help foster
greater autonomous motivation to use smoking cessation
medications, which is associated with increased medica-
tion use, and in turn, higher levels of abstinence [23].
Large-scale distribution of free over-the-counter nico-
tine replacement therapies (NRT) mailed to smokers
wanting to quit has had demonstrated success and re-
duces the barrier of geographic access to health services
[24, 25]. However, regulatory restrictions require a visit
to a prescriber to obtain a prescription for bupropion or
varenicline. The current study was conducted to test the
feasibility of a web-assisted tobacco intervention de-
signed to increase the use of prescription smoking cessa-
tion medications by having patients prompt a physician
to prescribe medication. Smokers motivated to quit were
directly engaged online and were required to visit their
physician within 3 weeks with a pre-populated form that
was converted to a prescription upon physician signature
in order to receive a free 12-week supply of bupropion
or varenicline, mailed to them by an online pharmacy.
The offer of free medication motivated the patient to ini-
tiate the dialogue with their physician. The online phar-
macy was able to courier medication to any jurisdiction
to increase the reach of the intervention and make it
more accessible to those living in rural and remote areas.
Given that this design is innovative and involves mul-
tiple steps with different providers, it was important to
establish feasibility prior to conducting a larger-scale
randomized clinical trial [26, 27]. We hypothesized that
this intervention would be a logistically feasible ap-
proach to provide prescription medication to a large
number of smokers over a wide geographic area.
Methods
Study design
An open-label trial was conducted to test the feasibility
of distributing by mail a free 12-week supply of bupro-
pion SR (Zyban) or varenicline (Champix, Chantix) to
smokers following a visit to a physician of their choice
for authorization of the prescription, in conjunction with
weekly motivational emails and with a 41-week follow-up
period to assess quit outcomes. The study was approved
by the Research Ethics Board at the Centre for Addiction
and Mental Health and was registered as a clinical trial
(ClinicalTrials.gov Identifier NCT01023659).
Participant recruitment
Adult smokers from Ontario, Canada, interested in quit-
ting could enroll at the study website (www.stopstudy.ca;
see Additional file 1). Study information, including an elec-
tronic copy of a recruitment poster that could be printed
and posted, was provided to healthcare professionals from
Selby et al. Implementation Science  (2015) 10:139 Page 2 of 14
public health units, community health centres, family
health teams and community pharmacies across Ontario.
Physicians were also informed about the study via the
Ontario College of Family Physicians newsletter.
Inclusion criteria required that participants be 18 years
of age or older, residents of Ontario, smoke at least 10
cigarettes per day, had smoked daily for at least the past
3 months, had smoked at least 100 cigarettes in their
lifetime and intended to quit smoking within the next
30 days. Exclusion criteria were self-reported: history of
brain injury or seizure(s); pregnancy, lactation or risk of
becoming pregnant; allergy to bupropion or varenicline;
current use of monoamine oxidase inhibitors (MAOIs),
thioridazine, varenicline or bupropion; severe liver im-
pairment; or history of anorexia and/or bulimia. The in-
clusion criteria were to mimic efficacy trial inclusion
criteria. The exclusion criteria were those listed as abso-
lute exclusions in the product monograph for bupropion
and varenicline at the time of the study.
Sample size
The number of participants enrolled in each group was
determined by the quantity of each medication available
for this study, considered sufficient for achieving the pri-
mary goal of determining the logistic feasibility of the
proposed distribution method. With a sample size of ap-
proximately 500, we could estimate a physician visit rate
of 50 % to within a 95 % confidence interval of ±4 %.
Intervention
A diagram outlining the participant flow is provided in
Fig. 1.
Safety considerations
A number of checks were incorporated into the design
to ensure that distribution was executed safely. The first
check was excluding participants who reported any one
of several contraindications to either medication during
the initial online assessment; this also minimized re-
sources from being wasted due to unnecessary physician
appointments. Should an individual have met eligibility
criteria by either deliberately or inadvertently submitting
an incorrect response, the physician acted as a secondary
check to screen for contraindications prior to prescrib-
ing the medication. Finally, the pharmacist acted as third
safety check by screening for potential drug interactions
and fraudulent prescriptions.
Online self-assessment and automated eligibility
determination
Prior to being asked to provide any personal informa-
tion, participants were required to provide informed
consent by selecting the “Yes” option to indicate their
agreement with the statement of consent. The website
presented frequently asked questions and contact infor-
mation of study personnel if individuals had additional
questions about study participation. The initial assess-
ment questions were designed to assess eligibility and
collect information on demographic and baseline smok-
ing characteristics. Participants were required to provide
an email address at which they could be contacted re-
garding their eligibility and for follow-up. Individuals
were not able to submit more than one assessment using
the same email address. Upon submitting the initial as-
sessment, an automated process informed participants
via email whether or not they were eligible. Those not
eligible were provided with a list of smoking cessation
resources they could access for assistance with quitting.
Personalized prescription form
Eligible smokers were immediately sent two documents
via email (see Additional file 2) with instructions to print
and bring to their physician within 3 weeks of study en-
rollment, after which the prescription would be void.
We estimated that 3 weeks would allow time to get an
appointment with a physician and still receive medica-
tion within the 30-day period during which participants
were planning to quit. The documents were as follows:
(1) a letter to the physician that provided information
about the study and (2) a personalized prescription form
for study medication. The patient name and address
fields were automatically filled in on the prescription
form based on information entered in the initial assess-
ment. The prescription form provided the option to se-
lect either bupropion (150 mg once daily for 3 days,
then 150 mg twice daily for the remainder of 12 weeks)
or varenicline (0.5 mg once daily for 3 days, 0.5 mg
twice daily for 4 days, then 1.0 mg twice daily for the re-
mainder of 12 weeks). Information about the potential
side effects and risks of each medication were presented
to the participant prior to them providing informed con-
sent. Given that the quantity of each medication was
limited, when the supply of one type of medication was
depleted, the option of selecting either medication was
removed from the website and on the prescription form.
The email to eligible participants also contained personal
login information for the study website where they could
access both documents at any time.
Patient visit to physician
In order to receive medication, participants were re-
quired to schedule a visit with a physician of their choice
to whom they would provide both study documents for
review, clarification and final determination of eligibility.
The letter explicitly stated that the physician had full
discretion to prescribe either medication to the patient
and that “the study intends to fully defer to the patient-
doctor relationship and thus leave the patient under
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your clinical care” (see Additional file 2). There were no
incentives provided to the physician but they were free
to bill the public healthcare system (Ontario Health In-
surance Plan) for the visit as per their respective eligibil-
ity and compensation model. To prescribe either
medication, the physician could checkmark the appro-
priate box on the prescription form to indicate the type
of medication (if a choice was still available) and
authorize the form by providing the date, their name,
signature and registration number. If either medication
was prescribed, the physician’s office was required to fax
the signed prescription form to the online pharmacy
(www.pharmacy.ca). The form included explicit instruc-
tions and the pharmacy name, fax and phone number.
Online pharmacy
The pharmacist verified the authenticity of the prescrip-
tion and contacted the physician’s office if any of the in-
formation on the form was incomplete or missing as per
their usual prescription verification practices. In accord-
ance with the Ontario College of Pharmacists’ standard
of practice, each participant was contacted by a pharma-
cist when dispensing medication to discuss possible al-
lergies, concomitant medications and provide relevant
medication counselling. Participants were cautioned re-
garding the possibility of drowsiness and to avoid driving
or operating machinery until they were reasonably cer-
tain that the medication did not affect their mental alert-
ness or physical coordination. The pharmacist asked the
1316 initial assessments 
submitted online
102 resubmissions by 89 unique 
individuals 
321 excluded
Do not plan to quit smoking within 
30 days: n=214
Contraindication(s) to medication:   
n=60
Did not meet additional eligibility
criteria: n=76
1214 unique individuals
369 did not receive 
medication
Did not visit physician: n=121




524 received prescription 
from online pharmacy














41 weeks: n=137; 
37.1% response
893 included; received 12 
weekly motivational emails
48 ineligible on first submission were
eligible with altered resubmission
Fig. 1 Flow chart of recruitment and follow-up. EOT end of treatment (15 weeks after study enrollment)
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participant to confirm their address and then couriered
the medication to the participant directly. An online
pharmacy allowed participants to receive their medica-
tion without the additional step of visiting a pharmacy
in person for dispensing, thereby eliminating a potential
barrier.
Behavioural support
All participants deemed eligible after completing the ini-
tial assessment, regardless of whether they received
medication or not, were sent a weekly motivational
email for 12 weeks. Emails commenced at 3 weeks after
study enrollment, the date by which prescriptions had to
be submitted for medication dispensing. See Table 1 for
examples of email messages sent. Each medication was
accompanied by a self-help booklet provided by the
manufacturer that included smoking cessation tips and
how to access web-based or telephone counselling
support.
Participant follow-up
Collection of follow-up data was attempted via email for
all participants at 7, 11, 15 and 41 weeks after enroll-
ment. We estimated that medications would be started
approximately 3 weeks after enrollment. Monthly con-
tact for the 12-week period thereafter was to monitor
any side effects and assess quit success. Follow-up at
41 weeks after enrollment (approximately 6 months after
the end of treatment) was to assess long-term quit suc-
cess. At each follow-up, participants were screened for
suicidal ideation because of post-marketing concerns re-
garding both bupropion and varenicline. Participants
who screened positive were advised to stop their medica-
tion and contact their physician immediately or report
to their nearest Emergency Department. One reminder
email was sent to non-respondents. Participants were
also provided a telephone number with the option of
completing the survey via telephone.
Outcome measures
The primary feasibility outcome was that at least 50 % of
eligible smokers planning to quit within 30 days would
report being able to schedule an appointment with a
physician before the prescription expired at 3 weeks
after enrollment. A 2008 survey found that 68 % of all
adults in Canada report being able to get an appoint-
ment with a physician within 7 days and 89 % within
30 days for routine care [28]. Based on this finding, we
estimated that at least 75 % of participants would be able
to schedule an appointment with a physician within
3 weeks after enrollment. Taking into consideration that
potential delays in calling the physician’s office (e.g. vary-
ing levels of motivation and failure to remember) and
conflict with other responsibilities and priorities (e.g.
employment and childcare) may lower this number, we
set 50 % as the threshold for feasibility. A low




1 Creating a smoke-free environment is important during your quit attempt. Make a decision not to smoke in your home and vehicle
and ask others to do the same. If your entire home cannot go smoke-free, explore areas where you can restrict smoking. At work,
avoid smoking areas during your breaks. Making your physical environment smoke-free can help reinforce your decision to quit
smoking.
2 Support systems are important during any big change. Identify all of the positive supports in your life and tell them you are
quitting smoking and need their support. Also identify any negative influences who may not want you to quit and figure out how
you are going to deal with them during this time. Take advantage of other supports available to you, such as Smoker's Helpline,
websites, your doctors or other healthcare providers. Surrounding yourself with positive and supportive people can help you quit
and stay quit.
3 Slips and lapses are a part of the quitting process and can be common. Use any slip or lapse as a learning experience.
Identify what happened, how you could have prevented the situation, and what you can do if you’re in the situation
again. Use these experiences to re-assess your quit plan and then try quitting again. It is important that you realize your
quit attempt is not over; refocus and restart immediately after your lapse. Remember, quitting smoking is a process not an
event and may take several attempts before you get it right.
4 One of the benefits of quitting smoking is the amount of money you save. The price of a pack of cigarettes is about C$8; so, that
means if you smoked about 15 cigarettes every day you would save about C$570 in 3 months (enough to purchase a new 32-inch
flat-screen TV) or save C$2180 in 1 year (enough for a long vacation abroad). Therefore, take advantage of quitting smoking
and reward yourself.
6 Your smoking may be associated with certain people, places, or things. These can act as triggers for you to want to smoke.
Identify your personal triggers and think about how you will deal with them. For example, change your day-to-day routine or find
alternative activities to smoking. Problem-solving ahead of time can help you deal with these situations when they arise and help
you quit and stay quit.
8 There are many good reasons why people want to quit smoking. Sometimes it’s easy to forget why you wanted to quit in the first
place. Write down your personal reasons for quitting and use them as reminders when things seem tough. Your reasons may
change over time so review your list regularly. Reminding yourself of all the reasons you want to quit can help you stay focused
on achieving your goal.
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proportion of physician visits was considered acceptable
in light of the negligible costs associated with enrolling
and following up with participants who do not visit a
physician. The following cut-off points were also set in
order to establish the logistic feasibility of the distribu-
tion method prior to proceeding with a larger study: (1)
ability to recruit a sample of approximately 500 partici-
pants within 6 months without using paid advertise-
ments, based approximately on the recruitment rate
from a study we conducted distributing free NRT that
required at least one visit to a pharmacy [29], assuming
one quarter as many individuals would be interested in
prescription cessation medications compared to NRT
[30] and a lower eligibility rate due to a greater number
of contraindications associated with bupropion and vare-
nicline; (2) eligibility rate of at least 70 %, similar to
comparable randomized trials comparing bupropion and
varenicline [31, 32]; (3) at least 45 % of eligible partici-
pants would receive medication, based on the assump-
tion that at least 50 % are able to visit a physician, and
of these, almost all would receive a prescription due to
the exclusion of those with contraindications at the ini-
tial assessment; and (4) no more than 7 days would be
typically required to reach the participant via telephone
for medication counselling and to confirm shipping ad-
dress, operationalized as the median number of days
between filling the prescription and sending the medica-
tion out for delivery, permitting most participants to
receive medication within 30 days.
Additional feasibility data collected included reasons
for not scheduling a visit with a physician, frequency of
medication delivery issues, and the average number of
days between study enrollment and prescription dispens-
ing and delivery. Logistic feasibility outcome data were
collected from participants at each follow-up survey (to
maximize the probability of having feasibility data for
each participant, given loss to follow-up) and also ex-
tracted from pharmacy records. Where a participant
provided conflicting responses at different follow-up
time points with respect to feasibility outcomes, the
earliest response is reported based on the assumption
that recall would be less accurate as time elapsed.
Acceptability of the motivational email component of
the intervention was assessed by asking participants at
each follow-up throughout the 12-week treatment
period to rate the helpfulness of the emails on a five-
point scale from 1 (not helpful at all) to 5 (very helpful).
Responses provided later in treatment replaced ratings
provided earlier in treatment, where applicable. Partici-
pants were also asked throughout and at the end-of-
treatment follow-up how much of the 12-week supply of
medication they had used. This was done because com-
pletion of treatment is a predictor of successful quitting
[33]. Participants were asked to select from several
response options provided, which were collapsed into a
smaller number of categories for analysis (none, less
than 1 week, 1 to less than 4 weeks, 4 to less than
8 weeks, 8 to less than 12 weeks, all 12 weeks). As
above, responses provided further along in treatment
replaced earlier responses, where applicable.
Treatment outcome was assessed in order to obtain an
estimate of treatment effect to inform a sample size cal-
culation for a future randomized trial. The outcome
variable related to the effectiveness of the intervention
was 7-day point prevalence of abstinence from smoking
at 41 weeks after enrollment, approximately 6 months
after the individual completed their 12-week course of
medication. Seven-day point prevalence abstinence was
defined as not having smoked even a puff over the previ-
ous 7 days.
Statistical analysis
Comparisons on baseline variables were made using chi-
square tests of association for categorical variables and t
tests for continuous variables to detect any differences
between participants who received medication and those
who did not, as well as between those who received bu-
propion versus varenicline. Respondents and participants
lost to follow-up at 41 weeks were similarly compared
on baseline characteristics to identify potential attrition
bias, and a comparison on baseline demographic charac-
teristics was made for participants who were able to visit
a physician versus those who were not. A one-sample
chi-square test was used to compare the observed versus
expected frequencies of smokers in each geographic re-
gion based on population estimates derived from the
2009–2010 Canadian Community Health Survey [34].
Data screening prior to analysis revealed that the pro-
portion of missing data values at baseline was highest
for annual household income (8 %) and employment sta-
tus (3 %); all other baseline variables had less than 1 %
missing data. Cases with missing data were deleted pair-
wise in all bivariate analyses. To attempt to minimize at-
trition bias, multiple imputation was used to address the
missing data for the analysis of the primary smoking ces-
sation outcome at 41-week follow-up; findings are pre-
sented alongside a complete case analysis. Multiple
imputation by chained equations was implemented using
Stata 12 (mi impute chained) to generate 20 imputed
datasets, with a burn-in period of 10 iterations. An in-
clusive strategy was used to impute data in an attempt
to maximize efficiency and reduce bias [35]; thus, add-
itional auxiliary variables from the baseline questionnaire
were included in the imputation model (e.g. number of
cigarettes per day, the longest previous quit attempt,
education level and employment status). Multiple imput-
ation analyses were conducted with Stata 12 [36]; all
other analyses were conducted with SPSS 15.0 [37].
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Level of significance was set at p < 0.05, with Bonferroni




A total of 1214 unique individuals submitted an initial
assessment between April and September 2010 (see
Fig. 1). To manage and ensure availability of the limited
supply of medication, enrollment was closed periodically
for varying lengths of time to monitor how many eligible
participants were filling prescriptions for each medica-
tion. Enrollment was highest in the first few months,
with 80 % recruitment by the end of June. The median
number of eligible participants that enrolled in the study
on days that enrollment was open was 12 (interquartile
range (IQR) 6–26) until the end of June and dropped to
4 (IQR 3–6) thereafter. Participants reported hearing
about the study from the following sources: friends or
family, 39.2 % (95 % confidence interval (CI) = 36.0–
42.4 %; n = 348); physician, 16.8 % (95 % CI = 14.3–
19.3 %; n = 149); public health unit, 15.1 % (95 % CI =
12.8–17.5 %; n = 134); other healthcare professional/
organization, 5.6 % (95 % CI = 4.1–7.2 %; n = 50); media
(newspaper, television and radio), 12.6 % (95 % CI =
10.4–14.8 %; n = 112); the Internet, 4.1 % (95 % CI =
2.8–5.4 %; n = 36); poster or flyer, 2.6 % (95 % CI = 1.5–
3.6 %; n = 23); others, 3.2 % (95 % CI = 2.0–4.3 %; n =
28); and don’t know/refuse, 0.8 % (95 % CI = 0.2–1.4 %;
n = 7).
Of the 1214 that submitted an initial assessment, 893
participants were eligible (73.6 %; 95 % CI = 71.1–
76.1 %) and successfully enrolled in the study. Individ-
uals were excluded for the following reasons: not plan-
ning to quit within 30 days, 17.6 % (95 % CI = 15.5–
19.8 %; n = 214); smoked fewer than 10 cigarettes/day,
4.5 % (95 % CI = 3.4–5.7 %; n = 55); did not smoke daily
over the past 3 months, 2.1 % (95 % CI = 1.3–2.9 %; n =
25); did not smoke cigarettes, 0.6 % (95 % CI = 0.2–
1.0 %; n = 7); had smoked fewer than 100 cigarettes in
their lifetime, 0.1 % (95 % CI = 0.0–0.2 %; n = 1); preg-
nant, 0.4 % (95 % CI = 0.1–0.8 %; n = 5); history of brain
injury, 0.8 % (95 % CI = 0.3–1.3 %; n = 10), seizure, 1.4 %
(95 % CI = 0.7–2.1 %; n = 17), bulimia or anorexia, 0.2 %
(95 % CI = 0.0–0.4 %; n = 2) or allergic reaction to bupro-
pion or varenicline, 0.7 % (95 % CI = 0.2–1.1 %; n = 8); or
current use of bupropion, varenicline, MAOIs or thiorida-
zine, 1.5 % (95 % CI = 0.8–2.2 %; n = 18).
Participant baseline characteristics are presented in
Table 2. Participants who received either medication
were older, had been smoking daily for longer and were
less likely to report that all or most of their friends
smoked. There were no statistically significant differ-
ences at baseline between participants who received
bupropion versus varenicline. The proportion of the
sample from each geographic region differed signifi-
cantly from the proportions expected based on popula-
tion estimates of smoking prevalence in each region
[34], χ2 (df = 4) = 167.02, p < 0.001. In particular, the pro-
portion of smokers from the city of Toronto was lower
than expected (6.0 % [95 % CI = 4.4–7.5 %; n = 53] vs.
17.5 %) and the proportion of smokers from Southwest-
ern Ontario was higher (25.1 % [95 % CI = 22.2–27.9 %;
n = 223] vs. 13.7 %); differences were minimal (<5 %) in
the remaining regions.
Follow-up response rates
The response rates at follow-up were as follows: 19.6 %
(95 % CI = 17.0–22.2 %; n = 175) at 7 weeks; 18.7 %
(95 % CI = 16.1–21.3 %; n = 167) at 11 weeks; 33.0 %
(95 % CI = 29.9–36.1 %; n = 295) at 15 weeks (end of
treatment); and 54.5 % (95 % CI = 51.3–57.8 %; n = 487)
at 41 weeks. The response rate at 41-week follow-up
among those that did not receive medication was sub-
stantially lower (37.1 %; 95 % CI = 32.2–42.1 %; n = 137)
compared to the bupropion (71.4 %; 95 % CI = 65.9–76.9 %;
n = 185) and varenicline (62.3 %; 95 % CI = 56.4–68.1 %;
n = 165) groups. Overall, 66.7 % (95 % CI = 63.7–69.8 %;
n = 596) of the sample had follow-up data for at least
one time point. Several differences emerged between re-
spondents and those lost to follow-up at 41 weeks (see
Table 3). Respondents were older and had a higher an-
nual household income; while they had been smoking
daily for a greater number of years, they also reported
longer periods of previous abstinence from smoking, re-
ported a longer time to first cigarette in the morning
and had a smaller proportion of friends who smoked.
Feasibility and acceptability outcomes
Among the entire sample with follow-up data, 79.7 %
(95 % CI = 76.1–83.3 %; n = 475) were able to get an ap-
pointment with a physician, 5.9 % (95 % CI = 3.8–8.0 %;
n = 35) chose not to see a physician and 14.1 % (95 %
CI = 11.0–17.2 %; n = 84) were unable to get an ap-
pointment with a physician in the required 3-week
time period. An additional 113 participants without
follow-up data who received medication could be as-
sumed to have visited a physician. Thus, at least 588
of all 893 eligible participants (65.8 %; 95 % CI =
62.7–68.9 %) visited a physician, though a somewhat
higher proportion is probable due to nonresponse at
follow-up by participants who had visited a physician
but did not receive medication. Excluding those who
chose not to make an appointment, those unable to
visit a physician did not significantly differ from those
who were able to visit a physician on any demo-
graphic characteristic except age, with those unable to
get an appointment being younger than those able to
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get an appointment, 38.35 (SD = 12.11) vs. 44.14 (SD =
12.38), p < 0.001.
Of those eligible for study medication, 58.7 % (95 %
CI = 55.5–61.9 %; n = 524) received either prescription
medication. Almost equal proportions received vareni-
cline (50.6 %; n = 265) or bupropion (49.4 %; n = 259).
All medication packages were successfully delivered,
with only 1.1 % (95 % CI = 0.2–2.1 %; n = 6) requiring
address clarification or reshipment. When a choice of
medication was offered, participants chose varenicline
(85.1 %; 95 % CI = 80.0–90.1 %; n = 165) more often than
bupropion (14.9 %; 95 % CI = 9.9–20.0 %; n = 29). Once
the available supply of varenicline was depleted at the
end of May, only bupropion was available.
Among those who received medication, 6.3 % (95 %
CI = 4.2–8.4 %; n = 33) were initially ineligible but had
altered their responses on resubmission to subsequently
become eligible. The most frequent reason (more than
one could apply) among these individuals for being ineli-
gible on original submission was not planning to quit
within 30 days (54.5 %; 95 % CI = 37.6–71.5 %; n = 18),
followed by contraindication to one of the medications
(27.3 %; 95 % CI = 12.1–42.5 %; n = 9), not currently
smoking daily and/or at least 10 cigarettes per day
(15.2 %; 95 % CI = 2.9–27.4 %; n = 5) and technical error
(6.1 %; 95 % CI = 0.0–14.2 %; n = 2). Contraindications
initially reported included an allergy to either medica-
tion, severe liver impairment, history of brain injury and
current use of bupropion, varenicline, thioridazine or an
MAOI.
Follow-up data were not available and therefore rea-
sons for not receiving either medication were unknown
for 59.1 % (95 % CI = 54.1–64.1 %; n = 218) of the 369
participants that did not receive medication. Of the 151
Table 2 Participant characteristics at baseline
Characteristic Received medication pa Type of medication pa
No (n = 365) Yes (n = 522) Bupropion (n = 258) Varenicline (n = 264)
Female, n (%) 196 (53.7) 307 (58.8) 0.130 150 (58.1) 157 (59.5) 0.758
Age (years), mean (SD) 38.6 (12.0) 44.2 (12.5) <0.001 44.4 (12.2) 44.0 (12.8) 0.729
Education level below high school diploma, n (%) 94 (25.9) 117 (22.4) 0.232 59 (22.9) 58 (22.0) 0.806
Annual household income ≤$20,000, n (%) 164 (48.8) 209 (42.9) 0.095 116 (46.4) 93 (39.2) 0.111
Employed, n (%)b 198 (54.2) 274 (52.5) 0.642 136 (52.7) 138 (52.3) 0.647
Geographic region, n (%) 0.495 0.418
Northern Ontario 46 (12.6) 50 (9.5) 26 (10.0) 24 (9.1)
Toronto 23 (6.3) 30 (5.7) 19 (7.3) 11 (4.2)
Central Ontario (excluding Toronto) 147 (40.3) 237 (45.2) 109 (42.1) 128 (48.3)
Eastern Ontario 57 (15.6) 76 (14.5) 37 (14.3) 39 (14.7)
Southwestern Ontario 92 (25.2) 131 (25.0) 68 (26.3) 63 (23.8)
Cigarettes per day, n (%) 0.365 0.764
10–19 35.9 (131) 32.2 (168) 31.4 (81) 33.0 (87)
20–29 51.0 (186) 51.9 (271) 51.6 (133) 52.3 (138)
30+ 13.2 (48) 15.9 (83) 17.1 (44) 14.8 (39)
Time to first cigarette in the morning ≤5 min, n (%) 51.0 (186) 46.0 (240) 0.291 47.3 (122) 44.7 (118) 0.817
Years since started smoking daily, mean (SD) 24.2 (12.0) 29.9 (12.4) <0.001 29.7 (12.1) 30.0 (12.7) 0.835
Fewer than three past quit attempts, n (%)c 220 (60.3) 270 (51.7) 0.012 140 (54.3) 118 (45.7) 0.251
Confidence in quitting (1–10), mean (SD) 7.5 (2.1) 7.8 (2.1) 0.019 7.8 (2.2) 7.8 (2.0) 0.865
Previous use of smoking cessation medication, n (%)d 186 (51.0) 284 (54.4) 0.311 142 (55.0) 142 (53.8) 0.774
Longest period of previous abstinence from
smoking <1 week, n (%)
115 (31.5) 149 (28.5) 0.342 75 (29.1) 74 (28.0) 0.793
All or most friends smoke, n (%) 180 (49.3) 164 (31.4) <0.001 80 (31.0) 84 (31.8) 0.749
Lives with other smoker(s), n (%) 219 (60.0) 279 (53.4) 0.053 140 (54.3) 139 (52.7) 0.712
History of drug or alcohol problem, n (%) 55 (15.1) 67 (12.8) 0.342 40 (15.5) 27 (10.2) 0.072
N varies due to missing data. All baseline data are missing for six participants
aThe Bonferroni-adjusted threshold for significance was p < 0.003
bEmployed full-time, part-time or self-employed
cAbstained from smoking for at least 24 h in an attempt to quit smoking
dNicotine patch, gum, inhaler, varenicline, bupropion
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who did have follow-up data, the reason for not receiv-
ing medication in the majority of cases was due to not
having visited a physician (80.1 %; 95 % CI = 73.8–
86.5 %; n = 121) and in much fewer cases due to the
physician not prescribing the medication (15.9 %; 95 %
CI = 10.1–21.7 %; n = 24) or for other reasons (4.0 %;
95 % CI = 0.9–7.1 %; n = 6). Reasons for not visiting a
physician are presented in Table 4. The most common
reason reported was not being able to arrange an ap-
pointment within 3 weeks. A small number of patients
did not have a family physician or were unable to access
or print the prescription form. While most patients who
did not visit a physician were unable to, some voluntarily
chose not to visit a physician, such as those who chan-
ged their mind about quitting or were not interested in
bupropion once varenicline was no longer available.
The median number of days between study enrollment
and having a prescription filled was 10 (IQR 5–16) and
for having it sent out for delivery was 14 (IQR 8–21). A
median of 2 days (IQR 1–5) was required after filling the
prescription to reach the participant for medication
counselling and to confirm shipping address.
The amount of the medication supply used was re-
ported by 57.6 % (95 % CI = 53.4–61.9 %; n = 302) of
participants that received medication, who reported
using the following amounts: none, 2.6 % (95 % CI =
0.8–4.5 %; n = 8); less than 1 week, 4.0 % (95 % CI = 1.8–
6.2 %; n = 12); 1 to less than 4 weeks, 27.2 % (95 % CI =
22.1–32.2 %; n = 82); 4 to less than 8 weeks, 26.5 %
(95 % CI = 21.5–31.5 %; n = 80); 8 to less than 12 weeks,
24.5 % (95 % CI = 19.7–29.4 %; n = 74); all 12 weeks,
14.6 % (95 % CI = 10.6–18.5 %; n = 44); and don’t know/
refuse, 0.7 % (95 % CI = 0.0–1.6 %; n = 2).
Based on an informal collection of data by the phar-
macy that was reported to investigators at the end of the
study, several issues arose that the pharmacist needed to
Table 3 Comparison of baseline characteristics for respondents and participants lost to follow-up at 41 weeks
Characteristics Enrolled (N = 887)a
Respondents (n = 505) Lost to follow-up at 41 weeks (n = 382) pb
Female, n (%) 287 (59.3) 216 (53.6) 0.088
Age (years), mean (SD) 43.95 (12.47) 39.46 (12.35) <0.001
Education level below high school diploma, n (%) 98 (20.3) 113 (28.1) 0.007
Annual household income ≤$20,000, n (%) 178 (39.7) 195 (52.0) <0.001
Employed, n (%)c 256 (54.2) 216 (55.1) 0.799
Geographic region, n (%) 0.980
Northern Ontario 62 (12.8) 54 (13.4)
Greater Toronto Area (GTA) 52 (10.7) 41 (10.2)
Central Ontario (excluding GTA) 119 (24.6) 104 (25.8)
Eastern Ontario 96 (19.8) 75 (18.6)
Southwestern Ontario 155 (32.0) 129 (32.0)
Cigarettes per day, n (%) 0.218
10–19 174 (36.0) 125 (31.0)
20–29 245 (50.6) 212 (52.6)
30+ 65 (13.4) 66 (16.4)
Time to first cigarette in the morning ≤5 min, n (%) 209 (43.2) 217 (53.8) 0.002
Years since started smoking daily, mean (SD) 27.19 (12.27) 22.80 (12.34) <0.001
Fewer than three past quit attempts, n (%)d 253 (52.3) 237 (58.8) 0.051
Confidence in quitting (1–10), mean (SD) 7.74 (2.13) 7.60 (2.07) 0.303
Previous use of smoking cessation medication, n (%)e 262 (54.1) 208 (51.6) 0.454
Longest period of previous abstinence from smoking <1 week, n (%) 120 (24.8) 144 (35.7) <0.001
All or most friends smoke, n (%) 157 (32.4) 187 (46.4) <0.001
Lives with other smoker(s), n (%) 258 (53.3) 240 (59.6) 0.062
History of drug or alcohol problem, n (%) 58 (12.0) 64 (15.9) 0.093
aN varies due to missing data. All baseline data were missing for six participants
bThe Bonferroni-adjusted threshold for significance was p < 0.003
cEmployed full-time, part-time or self-employed
dAbstained from smoking for at least 24 h in an attempt to quit smoking
eNicotine patch, gum, inhaler, varenicline, bupropion
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resolve in order to fill a prescription, which had the po-
tential to cause delays. Such issues included the follow-
ing: need to follow-up with physicians at the request of
patients when signed prescriptions were not faxed to the
pharmacy, additional counselling required when physi-
cians did not provide information to their patient re-
garding the medication and needing to call a physician
for recommendation when a contraindication was re-
ported by the participant. Though a precise frequency of
these occurrences was not provided, the average pro-
cessing time suggests that these issues did not regularly
cause extended delays. The pharmacy also reported hav-
ing received expired prescription forms that could not
be filled and the form was revised to clearly list the ex-
piry date. Several patients (less than 10) called the phar-
macy to request the contact information of a physician
that would participate in the study because their phys-
ician had declined to participate. These patients were re-
ferred to the College of Physicians and Surgeons of
Ontario to find physicians accepting new patients.
Ratings of the perceived helpfulness of the weekly mo-
tivational emails were available for 44.1 % (95 % CI =
40.9–47.4 %; n = 394) of participants. The mean rating
on a five-point scale was 2.78 (SD = 1.36). Ratings varied
widely; while 42.4 % (95 % CI = 37.5–47.3 %; n = 167)
rated the emails as not helpful at all or low on helpful-
ness (1 or 2), 27.7 % (95 % CI = 23.2–32.1 %; n = 109)
selected the midpoint on the scale and 29.9 % (95 %
CI = 25.4–34.5 %; n = 118) rated the emails helpful (4 or 5).
Smoking cessation outcomes
The 7-day point prevalence abstinence rate among re-
spondents at 41-week follow-up was 16.2 % (95 % CI =
9.9–22.2 %; n = 22) for the group that did not receive
medication, 30.3 % (95 % CI = 23.3–37.3 %; n = 50) for
the varenicline group and 24.3 % (95 % CI = 18.1–
30.5 %; n = 45) for the bupropion group. The abstinence
rates among those who received bupropion was 20.7 %
(95 % CI = 5.9–35.4 %; n = 6) for those who had a choice
of either medication and 25.0 % (95 % CI = 18.2–31.8 %;
n = 39) for those who did not have a choice; this differ-
ence was not statistically significant (p = 0.65). Abstin-
ence rates were very similar when missing data were
replaced using multiple imputation; the abstinence rate
at 41-week follow-up was 17.3 % (95 % CI = 14.1–
20.5 %) for the group that did not receive medication,
31.0 % (95 % CI = 27.0–35.0 %) for the varenicline group,
and 23.8 % (95 % CI = 20.2–27.4 %) for the bupropion
group. Those who received bupropion and had a choice
of medication had a quit rate of 21.5 % (95 % CI = 6.6–
36.5 %) and those without a choice had a quit rate of
24.3 % (95 % CI = 17.6–31.0 %); this difference was again
not statistically significant (p = 0.70).
Cost analysis
The cost per patient that received medication was
C$409.69. The cost per quitter ranged from approxi-
mately C$1003 (based on an overall quit rate of 24.0 %
at 41 weeks among respondents only) to C$1835 (based
on a quit rate of 13.1 % assuming non-respondents at
follow-up were still smoking). The cost increased by ap-
proximately C$33.70 for each patient seen by a physician
if they billed the government insurance plan for their
services.
Discussion
The current study establishes the feasibility of using a
patient-driven model that engages smokers directly for
Table 4 Reasons reported at follow-up for not visiting a physician to discuss prescription for study medication
Reason n Percentage (95 % CI) of those that
did not visit a physician (n = 121)
Percentage (95 % CI) of those
with follow-up data (n = 605)
Unable to see physician
Could not get an appointment within 3 weeks 40 33.1 (24.7–41.5) 6.6 (4.6–8.6)
Did not have a family physician 14 11.6 (5.9–17.3) 2.3 (1.1–3.5)
Did not receive confirmation email/unable to access
or print study prescription
14 11.6 (5.9–17.3) 2.3 (1.1–3.5)
Too busy to make an appointment within 3 weeks 3 2.5 (0.0–5.3) 0.5 (0.0–1.1)
Other 8 6.6 (2.2–11.0) 1.3 (0.4–2.2)
Chose not to see physician
Champix unavailable and did not want Zyban 16 13.2 (7.2–19.2) 2.6 (1.3–3.9)
Changed their mind about quitting 11 9.1 (4.0–14.2) 1.8 (0.7–2.9)
Did not want to or unable to use either medication 8 6.6 (2.2–11.0) 1.3 (0.4–2.2)
Other 1 0.8 (0.0–2.4) 0.2 (0.0–0.6)
Unknown 6 5.0 (1.1–8.9) 1.0 (0.2–1.8)
Reasons reported during follow-up interviews at 7, 11, 15 and 41 weeks. Where the same participant reported differing reasons at separate time points, the reason
provided at the earliest follow-up is reported
Selby et al. Implementation Science  (2015) 10:139 Page 10 of 14
delivery of evidence-based smoking cessation treatment
including prescription pharmacotherapy and behavioural
intervention. The majority of participants learned about
the study through family and friends or formal commu-
nication about the study targeted to participants (e.g.
posters and study website) rather than through health-
care providers, demonstrating that the decision to use
and prescribe medication to quit smoking was often
prompted by the patient themselves. To our knowledge,
few physicians declined to participate and only a small
proportion of participants who visited a physician were
not prescribed the medication, suggesting a high level of
acceptability of the intervention among physicians. This
also suggests that screening and excluding participants
based on contraindications to either medication success-
fully reduced unnecessary visits to the physician by those
for whom the medication was not suitable. A subsample
of participants reported having learned about the study
from a physician, though it is unknown if this was due
to study recruitment efforts directed at healthcare pro-
viders or if the impact on practice extended such that
physicians who had heard about the study from patients
then recommended medication to other patients. Fur-
ther research is needed to determine to what extent this
type of patient-mediated intervention has the capacity to
change physician practice across patients and over time.
The intervention was able to reach participants from a
wide range of communities across Ontario, and the only
region appreciably under-represented was the city of
Toronto, possibly due to a higher level of access to ser-
vices. The majority of the sample that responded to
follow-up was able to visit a physician to have the pre-
scription signed within the required time period. The
only demographic characteristic predictive of whether an
appointment with a physician could be scheduled was
age; greater difficulty getting an appointment may be
due to lower rates of having a regular medical doctor
among younger Canadians [38]. Very few technical diffi-
culties were reported with accessing or printing the pre-
scription, pharmacists were able to reach participants by
telephone in a timely manner for medication counsel-
ling, and all medication packages were successfully deliv-
ered. The amount of medication used varied, though
reasons for using less than the 12-week supply was not
available. While some likely stopped the medication due
to adverse effects or perceived lack of efficacy, some par-
ticipants may have started the medication later than the
study’s assumed start date for treatment and may ultim-
ately have used the entire supply.
For the most part, safety checks were successful and
the majority who reported contraindications did not go
on to receive medication. Though nine individuals who
initially reported medical contraindications resubmitted
an assessment and did go on to receive medication, we
cannot presume that the medication was prescribed in
error. For example, contraindications for bupropion and
varenicline were assessed jointly and thus an individual
may have been prescribed the medication to which they
had no contraindication. Furthermore, a physician with
a more detailed knowledge of the patient’s medical his-
tory may have used their clinical judgment and deemed
the medication acceptable. Individuals who initially re-
ported using one of bupropion, varenicline, thioridazine
or an MAOI may have been seeking a free supply of
medication they were already using. A list of medication
contraindications may be beneficial to include in the
documentation provided to physicians to further ensure
they screen for all possible contraindications rather than
rely solely on the decision of the study regarding eligibil-
ity for medication or on the pharmacist.
More often, altering responses to fit non-medical study
eligibility criteria (e.g. target quit date) occurred. These
resubmissions were identified post hoc by means of a
thorough examination of the personal information pro-
vided (i.e. names and birth date). Ideally, automated a
priori procedures would be in place to block resubmis-
sions and prevent prescriptions from being generated
and printed. In theory, this could be accomplished by
programming to detect and prohibit multiple submis-
sions based on an identifier, such as participant name or
Internet protocol (IP) address [39]. However, there are
inherent limitations with such strategies. Identifying in-
formation that is manually entered is easy to alter, which
we observed in many resubmissions. While a correct
name is needed to fill a prescription and not as liable to
falsification, we did encounter unique individuals with
the same first and last names. Therefore, blocking sub-
missions based on a combination of two separate identi-
fiers would be beneficial, to minimize the chance of
preventing legitimate submissions. Limiting submissions
based on IP address or by using cookies also has limita-
tions [39], including preventing individuals in the same
household from participating [39] and trying to quit
smoking simultaneously. However, in the current study,
it is also possible that alteration of quit date may have
demonstrated that the offer of free medication was a
motivator for change, prompting an earlier quit attempt,
rather than an attempt to falsify information.
Overall, findings from the current study support the
feasibility of using this distribution method in a future
larger trial to establish the effectiveness of this interven-
tion for improving quit rates. A randomized trial is re-
quired in order to conclude that either medication was
superior to the control condition, particularly given that
the reasons for not receiving medication were largely
unreported due to low response rate in that group.
Given the possibility of selection bias, randomization is
also necessary to make conclusions regarding the
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relative effectiveness of bupropion versus varenicline.
While there was clearly a strong preference for vareni-
cline in the current sample, this was likely due to the
relative novelty of the medication at the time in Canada.
Estimates of treatment effect obtained in the current
study will be used to ensure that a larger randomized
trial is sufficiently powered.
One factor to consider for future implementation is
the length of time provided before the prescription is
considered void. Extending the prescription expiry date
may be warranted as not being able to make an appoint-
ment within the required 3-week time period was the
most common reason for not having visited a physician,
though overall it was not reported frequently. However,
further research is needed to determine whether extend-
ing the period does in fact lead to an appreciable in-
crease in visits to a physician. Extending the initial
period may require adjustments to the methodology to
take into account greater variability between participants
in the length of time between enrollment and the start
of treatment. One option may be to have the pharmacist
log in online to indicate when a prescription has been
filled to activate the start of motivational emails and de-
termine the timing of follow-ups rather than being based
on enrollment date. In addition, consideration on how
to manage supply and capacity to fill prescriptions is re-
quired in future implementation of this method. While
the current study managed the limited medication supply
by periodically closing down enrollment due to uncer-
tainty regarding the proportion of eligible participants that
would fill a prescription, further pilot testing may be bene-
ficial as this rate is likely to differ in other jurisdictions,
using other recruitment methods etc. Placing a limit
on the number of enrollments per day or week is a
potential alternative strategy to shutting enrollment
down completely. That adjunct motivational emails
were not predominantly rated very helpful is similar
to previous findings [40]. Additional research may
determine how to improve the benefit to participants
by altering the content or format of the messages or
making these emails an optional component of the
intervention.
Some limitations are noted with respect to the design
of this distribution method. While online access affords
an efficient, cost-effective and convenient format for
assessing eligibility and enrolling in a program, its reach
is limited to those who have access to the Internet and
thus may be less accessible to lower-income households.
In 2012, 83 % of Canadian households had access to the
Internet at home; however, this proportion drops to
58 % in homes with household incomes in the lowest
quartile (≤$30,000/year) [41]; however, this may be miti-
gated by access to the Internet outside the home such as
in public libraries and community centres. Reach is also
poorer in rural areas [41] and among older adults, who
are less likely to be online [42].
Additional limitations of the current feasibility study
existed. The response rates were very poor during the
12-week treatment period, and future studies may bene-
fit by providing an incentive to improve response rate.
The response rate did considerably increase at 41-week
follow-up without any change to our methodology; the
reason for this is unclear though we speculate that sea-
sonality may partially account for this finding as surveys
throughout treatment were largely conducted during the
summer months. The response rate among those who
did not receive medication remained relatively low though
and thus the reasons for not receiving medication remains
unknown for a large proportion of this group. This loss to
follow-up may have led to underestimation of barriers to
participation and additional barriers that went unreported
may exist. Furthermore, significant differences between re-
spondents and non-respondents indicate the possibility of
bias in the reported outcomes. Findings may also not be
generalizable to settings without a publicly funded health-
care system and universal access to a physician. Abstin-
ence was not biochemically verified in the current study.
A future trial designed to assess effectiveness of this inter-
vention could verify abstinence by collecting saliva sam-
ples through the mail to determine salivary cotinine levels
[43]. Finally, without knowing the number of smokers to
whom information about the study was disseminated, the
fact that we were able to recruit 500 eligible smokers
within 6 months is not an entirely informative indicator of
the success of our recruitment efforts. That is, it does not
tell us what proportion who heard about the study
attempted to enroll.
While an Internet-based pharmacy was shown to be
an effective and efficient means to distribute prescription
medication over a wide geographic area in the current
study, recent legislative changes have authorized phar-
macists in some jurisdictions to prescribe varenicline
and bupropion for smoking cessation. This presents the
option of a pharmacist distributing medication directly
to the patient without the need to visit a physician. The
availability of pharmacists, often without the need for a
scheduled appointment, could enhance the accessibility
of the intervention and dispensing in-person would elim-
inate delivery costs. The feasibility of this method of distri-
bution is supported by our previous experience facilitating
pharmacy-based smoking cessation interventions offering
NRT and counselling [29].
Conclusions
The current study supports the feasibility of an innovative
method of distributing free prescription medications to
smokers whereby those interested in quitting complete an
online assessment, bring a prescription to their physician
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to assess the suitability of the medication, which is then
dispensed and delivered by an Internet-based pharmacy. It
demonstrates that using Internet-based pharmacies with
the capability to dispense by mail can be used to distribute
prescription medications for smoking cessation to
smokers across vast geographic areas, including both
major urban centres and smaller underserved rural
communities to reduce geographic disparity in access to
services. This method of distribution maintains some of
the advantages of Internet-based treatment delivery, in-
cluding increased efficiency and lower cost, but over-
comes a limitation by integrating in-person clinical
contact with a physician and brief telephone counselling
with a pharmacist. The current model can readily be
scaled up for state- or nationwide implementation, in-
cluding in jurisdictions where cessation medication
costs are covered by governmental health agencies, in
an effort to enhance smoking cessation rates at a
population-wide level.
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